Technical Information

InertSearch (Application Library)

Index

Application

Micro GC

Document No. Index

LB401 - 500 of Application List

No. Description Column
LB401 Analysis of Preservatives and Sweetener (InertSustain AQ-C18) InertSustain AQ-C18
LB402 Analysis of Preservatives and Sweetener (InertSustain AQ-C18) InertSustain AQ-C18
LB403 Analysis of Preservatives and Sweetener (Inertsil ODS-4) Inertsil ODS-4
LB404 Analysis of Preservatives and Sweetener (Inertsil ODS-SP) Inertsil ODS-SP
LB405 Analysis of Phenolic antioxidants InertSustainSwift C18
LB406 Analysis of Hippuric acid InertSustain AQ-C18 HP
LB407 Analysis of Fluconazole (Under the Condition of the Japanese Pharmacopoeia, Fluconazole Capsules) Inertsil WP300 C18
LB408 Analysis of Fluconazole (Under the Condition of the Japanese Pharmacopoeia) InertSustainSwift C18
LB409 Analysis of Mesalazine (Under the Condition of the draft for the Japanese Pharmacopoeia, Mesalazine Extended-release Tablets) Inertsil ODS-4
LB410 Analysis of Medroxyprogesterone acetate (Under the Condition of the draft for the Japanese Pharmacopoeia) Inertsil WP300 C18
LB411 Analysis of Medroxyprogesterone acetate (Under the Condition of the draft for the Japanese Pharmacopoeia) Inertsil WP300 C18
LB412 Analysis of Eplerenone (Under the Condition of the draft for the Japanese Pharmacopoeia) InertSustainSwift C18
LB413 Analysis of Eplerenone (Under the Condition of the draft for the Japanese Pharmacopoeia) InertSustainSwift C18
LB414 Analysis of Esomeprazole magnesium (Under the Condition of USP 38-NF33, Esomeprazole magnesium Extended-release Tablets) InertSustain C18
LB415 Analysis of Methotrexate (Under the Condition of the draft for the Japanese Pharmacopoeia, Methotrexate Tablets) Inertsil ODS-4
LB416 Analysis of Vitamin K (InertSustain AQ-C18) InertSustain AQ-C18
LB417 Analysis of Vitamin K (InertSustainSwift C18) InertSustainSwift C18
LB418 Analysis of Vitamin K (Inertsil WP300 C18) Inertsil WP300 C18
LB419 Analysis of Acetaminophen (Under the Condition of the Japanese Pharmacopoeia) (InertSustain C18) InertSustain C18
LB420 Analysis of Acetaminophen (Under the Condition of the Japanese Pharmacopoeia) (InertSustainSwift C18) InertSustainSwift C18
LB421 Analysis of Nonsteroidal anti-inflammatory drug (InertSustain Phenylhexyl) InertSustain Phenylhexyl
LB422 Analysis of Nonsteroidal anti-inflammatory drug (InertSustain C18) InertSustain C18
LB423 Analysis of Nonsteroidal anti-inflammatory drug (InertSustain Phenyl) InertSustain Phenyl
LB424 Analysis of Eplerenone(Under the Condition of the Japanese Pharmacopoeia 17th edition, Eplerenone Tablets) Inertsil ODS-3
LB425 Analysis of Diflorason Diacetate(Under the Condition of the Japanese Pharmacopoeia 17th edition) InertSustain C18
LB426 Analysis of Diflorason Diacetate(Under the Condition of the Japanese Pharmacopoeia 17th edition) InertSustain C18
LB427 Analysis of Zonisamide InertSustain AQ-C18
LB428 Analysis of Zonisamide InertSustain AQ-C18
LB429 Analysis of Tulobuterol(Under the Condition of the Japanese Pharmacopoeia 17th edition) InertSustain C18
LB430 Analysis of Tulobuterol Hydrochloride(Under the Condition of the Japanese Pharmacopoeia 17th edition) InertSustain C18
LB431 Analysis of Haloperidol(Under the Condition of the Japanese Pharmacopoeia 17th edition) Inertsil ODS-4
LB432 Analysis of Haloperidol(Under the Condition of the Japanese Pharmacopoeia 17th edition, Haloperidol Tablets) Inertsil ODS-4
LB433 Analysis of Povidone(Under the Condition of the Japanese Pharmacopoeia 17th edition, (4) 1-Vinyl-2-pyrrolidone) InertSustain AQ-C18
LB435 Analysis of Povidone(Under the Condition of the Japanese Pharmacopoeia 17th edition, (6) 2-Pyrrolidone) InertSustain AQ-C18
LB436 Analysis of Mesalazine(Under the Condition of the Japanese Pharmacopoeia, (7) Aniline) InertSustain C18
LB437 Analysis of BSA Digests (InertSustain AQ-C18) InertSustain AQ-C18
LB438 Analysis of BSA Digests (InertSustainSwift C18) InertSustainSwift C18
LB439 Analysis of Myoglobin Digests (InertSustain AQ-C18) InertSustain AQ-C18
LB440 Analysis of Myoglobin Digests (InertSustainSwift C18) InertSustainSwift C18
LB441 Analysis of Aflatoxin M1(InertSustain AQ-C18) InertSustain AQ-C18
LB442 Analysis of Aflatoxin M1(Inertsil ODS-3) Inertsil ODS-3
LB443 Analysis of Nucleotide InertSustain AQ-C18
LB444 Analysis of Pazufloxacin mesilate(Under the Condition of the draft for the Japanese Pharmacopoeia) Inertsil ODS-2
LB445 Analysis of Pazufloxacin mesilate (Under the Condition of the Japanese Pharmacopoeia 18th edition) Inertsil ODS-3
LB446 Analysis of Hydrocortisone butyrate(Under the Condition of the draft for the Japanese Pharmacopoeia) Inertsil ODS-3 HP
LB447 Analysis of Mesalazine(Under the Condition of the draft for the Japanese Pharmacopoeia, (6) 2-Aminophenol and 4-Aminophenol) InertSustainSwift C18 HP
LB448 Analysis of Mesalazine(Under the Condition of the draft for the Japanese Pharmacopoeia, (8) 3-Aminophenol, 3-Aminobenzoic acid, Gentisic acid, Salicylic acid, other related substances and total related substance) InertSustain C8
LB449 Analysis of Lansoprazole(Under the Condition of the Japanese Pharmacopoeia) InertSustain C18
LB450 Analysis of Tranexamic acid(Under the Condition of the Japanese Pharmacopoeia) InertSustain AQ-C18
LB451 Analysis of Tranexamic acid(Under the Condition of the Japanese Pharmacopoeia) InertSustain AQ-C18
LB452 Analysis of Tranexamic acid(Under the Condition of the Japanese Pharmacopoeia, Tranexamic acid Tablets) InertSustain AQ-C18
LB453 Analysis of Tranexamic acid(Under the Condition of the Japanese Pharmacopoeia, Tranexamic acid Capsules) Inertsil ODS-4
LB455 Analysis of Polar Peptides InertSustain AQ-C18
LB456 Analysis of Benzenediols InertSustain C18
LB457 Analysis of Hydroxynaphthoquinones InertSustain C18
LB458 Analysis of Glyburide (Under the Condition of USP 39-NF34) Inertsil C8
LB459 Analysis of Acetaminophen (Under the Condition of USP 39-NF34, Acetaminophen Capsules) Inertsil ODS-3
LB460 Analysis of Estradiol (Under the Condition of USP 39-NF34) Inertsil ODS-3
LB461 Analysis of Phenylephrine Hydrochloride (Under the Condition of USP 39-NF34, Phenylephrine Hydrochloride Injection) InertSustain C18
LB462 Analysis of Cephalexin (Under the Condition of USP 39-NF34) InertSustain C18
LB463 Analysis of Ibuprofen (Under the Condition of USP 39-NF34, Ibuprofen Oral Suspension) InertSustain C8
LB464 Analysis of Ultraviolet absorbers InertSustain C18
LB465 Analysis of Fungicides InertSustain C18
LB466 Analysis of Oxalic acid InertSustain Amide
LB467 Analysis of Vitamin D Inertsil ODS-HL
LB468 Analysis of Vitamin K(InertSustainSwift C8) InertSustainSwift C8
LB469 Analysis of Vitamin K(Inertsil ODS-HL) Inertsil ODS-HL
LB470 Simultaneous analysis of Amino acids derivatized with 4-fluoro-7-nitro-2,1,3-benzoxadiazole (NBD-F) InertSustainSwift C18
LB471 Analysis of Tramadol Hydrochloride (Under the Condition of the draft for the Japanese Pharmacopoeia) InertSustain C8
LB472 Analysis of Tramadol Hydrochloride (Under the Condition of the draft for the Japanese Pharmacopoeia) InertSustainSwift C8
LB473 Analysis of Solifenacin Succinate (Under the Condition of the draft for USP) InertSustain Phenyl
LB474 Analysis of Solifenacin Succinate (Under the Condition of the draft for USP) InertSustain Phenylhexyl
LB475 Analysis of Solifenacin Succinate (Under the Condition of the draft for USP) Inertsil Ph-3
LB476 Analysis of Solifenacin Succinate (Under the Condition of the draft for USP) Inertsil Ph
LB477 Analysis of Povidone(Under the Condition of the Japanese Pharmacopoeia 17th edition, (7) Formic acid) InertSphere FA-1
LB479 Analysis of Lactosucrose InertSustain Amide
LB480 Analysis of 13 kinds of Aldehydes (Directed by Pre-Column Method with DNPH) InertSustain C18
LB481 Analysis of Bromate ion in tap water SYPRON AX-1
LB482 Analysis of Glycyrrhiza (Under the Condition of the Japanese Pharmacopoeia 17th edition) Inertsil ODS-4
LB483 Analysis of Minocycline Hydrochloride (Under the Condition of the Japanese Pharmacopoeia 17th edition) InertSustainSwift C8
LB484 Analysis of Catecholamine metabolite InertSustainSwift C18
LB485 Analysis of Pyridoxal Phosphate Hydrate (Under the Condition of the Japanese Pharmacopoeia, (4) Related subatances) InertSustain AQ-C18
LB486 Analysis of Clomipramine Hydorochloride (Under the Condition of the Japanese Pharmacopoeia, Clomipramine Hydorochloride Tablets) Inertsil ODS-3
LB487 Analysis of Verapamil Hydrochloride (Under the Condition of the Japanese Pharmacopoeia, Verapamil Hydrochloride Tablets) InertSustain C18
LB488 Analysis of Sucralose InertSustain C18
LB489 Analysis of Azosemide (Under the Condition of the draft for the Japanese Pharmacopoeia, Azosemide Tablets) InertSustain C18
LB490 Analysis of Nucleosides InertSustain Amide
LB491 Analysis of Nucleobases InertSustain Amide
LB493 Analysis of Tryptophan metabolites InertSustain Amide
LB494 Analysis of Corticosteroids Inertsil ODS-HL
LB495 Analysis of Tyramine and Histamine InertSustain Amide
LB496 Analysis of Tetrodotoxin InertSustain Amide
LB497 Analysis of Amino acids InertSustain Amide
LB498 Analysis of Analysis of Tasty Components InertSustain Amide
LB499 Analysis of Purine bases InertSustain Amide
LB500 Analysis of Melamine related compounds InertSustain Amide